Alphamab Oncology (Stock Code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

AZ booked $540 million from Enhertu in the fourth quarter, a rise of 54%, and $1.99 billion for the full year out of total ...

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on February 4, 2025, the Compensation ...

T-DM1 sustained the improvement in invasive disease-free survival over trastuzumab in HER2-positive early breast cancer.

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

Twenty-four-year-old Caitlyn Micholson is fighting cancer and for a chance to access lifesaving alternative treatment that is ...

The U.S. Food and Drug Administration has approved Enhertu (trastuzumab deruxtecan) for the treatment of adult patients with ...

Union Finance Minister Nirmala Sitharaman on Saturday, February 1 announced 10,000 additional seats in medical colleges as ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

India's Union Budget 2025-26 proposes cutting 7 customs tariff rates for industrial goods, reducing total slabs to 8, ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...